Immunohistochemistry for lymphoma characterization should include different types of markers: a) markers to demonstrate B-cell origin (e.g. CD19, CD20 and CD79a); b) markers to characterize expanded B ...

These markers often start with the letters CD. For instance, B-cell markers (CD20 and CD79a), T-cell markers (CD3 and CD5), and other markers like CD23, bcl-2, CD10, cyclinD1, CD15, CD30, ALK-1, CD138 ...

Regeneron Pharmaceuticals (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering ...

TCF21 (transcription factor 21) is a bHLH (basic helix-loop-helix) protein required for the developmental specification of cardiac fibroblasts (CFs) from epicardial progenitor cells that surround the ...

Recently, the novel CD19CAR-T cells incorporated with B-cell costimulatory molecules of CD79A/CD40 demonstrated superior antitumor activity in the B-cell lymphoma model compared with CD28 or 4-1BB.

Designing monospecific CARs against three individual targets (CD19, CD79a, and CD79b), the team confirmed that they had anti-tumor activity in mouse xenograft models. They also saw, however, that ...

bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR ...

On gross examination, a biopsy of affected lymph nodes or other tissues exhibits a fleshy and soft cut surface, with effacement of the normal architecture. 2 DLBCL is described as a tumor of large B ...